A Study in Subjects With Neurogenic Orthostatic Hypotension

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
CuraSen Therapeutics, Inc.
Study ID
NCT07089043
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Neurogenic Orthostatic Hypotension

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • CST-3056 — DRUG
    Administered as an oral solution
  • Placebo — DRUG
    Administered as an oral solution

Study Details

This is a study to evaluate the effects of CST-3056 on orthostatic symptoms and signs in subjects with neurogenic orthostatic hypotension (nOH).

Key Dates

Start date
Sep 12, 2025
Status verified
May 2026
Primary completion
May 31, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
12 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: CST-3056
    Subjects will receive single doses of CST-3056 over 3 days and on the Optimal Dose Day (Day 5)
  • Placebo Comparator: Placebo
    Subjects will receive a single dose of placebo on 1 day

Primary Outcome Measure

Change from Baseline in Standing Systolic Blood Pressure [ Time Frame: Baseline and 1, 2, 3, and 4 hours post-dose on Days 1 to 4 ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
CuraSen Investigational SiteScottsdaleArizona85251
Principal Investigator
CuraSen Investigational SiteFarmington HillsMichigan48334
Principal Investigator
CuraSen Investigational SiteEatontownNew Jersey07724
Principal Investigator
CuraSen Investigational SiteNew YorkNew York10019
Principal Investigator
CuraSen Investigational SiteNashvilleTennessee37240
Principal Investigator

Find similar trials in Scottsdale, AZ

By research site
CuraSen Investigational Site· Scottsdale, AZCuraSen Investigational Site· Farmington Hills, MICuraSen Investigational Site· Eatontown, NJCuraSen Investigational Site· New York, NYCuraSen Investigational Site· Nashville, TN

Related Studies